Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Scott Koppel

Podiatrist Gainesville, FL Doctor of Podiatric Medicine

NPI 1295732741 CMS profile 855782

500 Nw 43Rd Street, Ste 2, Gainesville, FL 32607

Open in the dashboard

General payments

$5,794

130 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scott Koppel of Gainesville, FL is reported in the CMS Open Payments database as having received $5,794 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $469 12
2024 General $622 19
2023 General $375 12
2022 General $646 14
2021 General $2,051 28
2020 General $639 17
2019 General $992 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scott Koppel
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Scott Koppel were reported at $469. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Scott Koppel Podiatrist median Middle half National median
2019 $992 $196 $72–$601 $163
2020 $639 $118 $38–$335 $114
2021 $2,051 $169 $57–$573 $132
2022 $646 $220 $74–$782 $149
2023 $375 $208 $71–$635 $160
2024 $622 $237 $87–$681 $164
2025 $469 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $1,447 25 payments
  2. Arthrex, Inc. $1,200 1 payment
  3. Medtronic, Inc. $715 22 payments
  4. Smith+Nephew, Inc. $403 22 payments
  5. Integra LifeSciences Corporation $365 6 payments
  6. Medtronic Vascular, Inc. $272 12 payments
  7. Stimwave Technologies Incorporated $243 6 payments
  8. Kerecis Limited $142 1 payment
  9. Bioventus LLC $127 2 payments
  10. AngioDynamics, Inc. $124 1 payment
  11. Other $755 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,376 126 payments
  2. Education $1,223 2 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $195 2 payments
Products named General payments · program years 2019–2025
  1. Puraply $507 9 payments
  2. ClosureFast $411 12 payments
  3. PANTA NAIL $365 6 payments
  4. HALLU-LOCK $365 6 payments
  5. TOTAL FOOT SYSTEM $365 6 payments
  6. CADENCE ANKLE REPLACEMENT SYSTEM $365 6 payments
  7. SALTO TALARIS TOTAL ANKLE PROSTHESIS $365 6 payments
  8. Affinity $315 6 payments
  9. VENASEAL EndoVenous Therapies $279 9 payments
  10. VenaSeal EndoVenous Therapies $243 10 payments
  11. Other $5,308 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

806

Median for Podiatry: 160

Drug cost

$9,294

Median for Podiatry: $2,368

Branded share of claims

13.6%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Terbinafine Hcl Generic 172 $1,824
Pregabalin Generic 78 $1,658
Duloxetine Hcl Generic 78 $1,261
Cephalexin Generic 29 $657
Gabapentin Generic 65 $650
Celecoxib Generic 27 $500
Doxycycline Hyclate Generic 31 $456
Ciclopirox Generic 14 $429
Prednisone Generic 72 $316
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 36 $313

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$1,140,335

Of which drugs: $700,145

Medicare patients

493

Average age 75

Services billed

3,433

286 women, 207 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 39%
Ischemic heart disease 30%
Chronic kidney disease 28%
Depression 22%
Atrial fibrillation 18%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Novachor, per square centimeter Q4194 Office 18 570 $457,497
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 87 516 $382

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KRYSTEXXA
  • Amgen Inc. $46
$46 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record